What's in a Name? The Science and Ethics Behind Renaming Monkeypox to Mpox

Language carries weight far beyond its literal meaning, and nowhere is this more consequential than in the naming of infectious diseases. When the World Health Organization (WHO) announced in November 2022 that it would formally adopt "mpox" as the preferred designation for the illness previously called monkeypox, the decision drew reactions ranging from scientific applause to public confusion. Yet the reasoning behind that choice—rooted in decades of lessons about stigma, misinformation, and geopolitical sensitivity—deserves careful examination by anyone who cares about effective public health communication.

The Problem With the Old Name

Monkeypox was first identified in 1958 in laboratory monkeys used for research, and the name stuck when the disease was later detected in humans. For decades, it remained a relatively obscure illness primarily affecting populations in Central and West Africa, and the nomenclature attracted little scrutiny. That changed dramatically in 2022, when a significant outbreak spread across more than 100 countries, including the United States, in a matter of months.

As cases surged globally, public health officials and researchers began raising alarms about the name's unintended consequences. Critics pointed to two distinct problems. First, the word "monkeypox" implied that monkeys were the primary reservoir or vector of the disease—a scientifically inaccurate association, since rodents are the more likely animal reservoir. Second, and more urgently, the name was being weaponized in media coverage and social media discourse in ways that associated the disease with Africa, with African people, and with specific racial groups. Several African health leaders and international organizations formally objected, arguing that such framing perpetuated harmful stereotypes and discouraged affected communities from seeking care.

WHO's Evolving Guidelines on Disease Naming

The WHO has been refining its approach to disease nomenclature since at least 2015, when it published guidelines explicitly discouraging names that reference geographic locations, specific animal species, or identifiable population groups. Those guidelines emerged from painful experience: names like "Spanish flu," "MERS" (Middle East Respiratory Syndrome), and "swine flu" had each, in their own way, generated diplomatic tensions, economic disruptions, and discrimination against specific communities.

The 2022 mpox situation put those guidelines to a real-world test under pressure. The WHO convened consultations with member states, scientific experts, and affected communities before settling on "mpox" as a transitional name, allowing both terms to be used simultaneously for a period before monkeypox is fully phased out. The deliberate, consultative nature of the process itself signaled a shift: disease naming is no longer treated as a purely taxonomic exercise but as a matter of public health ethics.

How Names Shape Behavior—and Funding

The influence of disease nomenclature extends well beyond optics. Research consistently demonstrates that how a disease is named affects public willingness to seek testing, the speed of political response, and even the allocation of research funding.

During the 2022 outbreak in the United States, public health messaging struggled in part because early framing linked mpox almost exclusively to gay and bisexual men. While that population was disproportionately affected in the initial wave, the narrow framing discouraged others from recognizing their own risk and delayed a broader public health response. Naming conventions and demographic framing interact in ways that can create blind spots with serious consequences.

Funding dynamics are similarly affected. Diseases associated with marginalized or foreign populations have historically attracted fewer domestic research dollars. Renaming a disease to remove stigmatizing associations can, over time, broaden the perceived constituency of concern and attract more diverse investment in diagnostics, therapeutics, and vaccines.

The Backlash and the Counterarguments

Not everyone welcomed the name change. Some scientists argued that renaming a well-established pathogen mid-outbreak risked creating confusion in medical literature, complicating database searches, and undermining continuity in epidemiological tracking. These are legitimate operational concerns. Medical records systems, laboratory reporting infrastructure, and academic publications had been built around a specific term for over six decades.

Others questioned whether renaming represented a form of "scientific erasure"—a sanitizing of history that might obscure important epidemiological context. These critiques deserve acknowledgment even by those who ultimately support the change. Effective disease renaming requires parallel efforts to update databases, retrain search algorithms, and educate clinicians—none of which happen automatically.

The WHO acknowledged these challenges and built in a transition period precisely to allow institutions to adapt. The Centers for Disease Control and Prevention (CDC) in the United States updated its official communications accordingly, and most major medical journals began adopting the new terminology by early 2023.

Lessons for Future Outbreak Communication

The mpox renaming episode offers several durable lessons for public health communicators, policymakers, and journalists alike.

Stigma is a transmission barrier. When disease names generate fear or shame around specific communities, members of those communities are less likely to seek testing or treatment—which accelerates spread rather than containing it. Reducing stigma is not a social nicety; it is a core epidemiological strategy.

Naming decisions should be proactive, not reactive. The 2015 WHO guidelines existed precisely to prevent situations like the 2022 mpox crisis, yet the old name persisted until external pressure forced a change. Future pathogens should receive stigma-conscious names from the moment of identification, before public discourse has time to calcify around harmful associations.

Transparency in the naming process builds trust. The WHO's consultative approach—engaging affected communities, governments, and scientists before finalizing a new name—modeled a form of inclusive governance that strengthened rather than undermined public confidence in the decision.

Global connectivity demands globally responsible language. In an era when a disease can spread across continents within weeks and social media amplifies stigmatizing content instantaneously, the choice of a disease name is effectively a global communication decision. American public health officials, media organizations, and healthcare providers all have a role in using terminology that reflects both scientific accuracy and human dignity.

A Standard Worth Maintaining

The shift from monkeypox to mpox may appear, on the surface, to be a minor administrative update. In reality, it represents the culmination of a long-overdue reckoning with the power of language in medicine. The names we assign to diseases are not neutral labels—they encode assumptions, trigger associations, and shape the behavior of patients, providers, policymakers, and the public.

As novel pathogens continue to emerge in an increasingly interconnected world, the standards established through the mpox renaming process offer a valuable template. Evidence-based disease communication requires not only accurate data but precise, equitable, and carefully chosen words. Getting the name right from the start may be one of the most cost-effective public health interventions available.